Citalopram

證據等級: L5

預測適應症: 5 個

Citalopram: From Depression to Obsessive-Compulsive Disorder

One-Sentence Summary

Citalopram is a selective serotonin reuptake inhibitor (SSRI) whose well-established original use is the treatment of depression (major depressive disorder); this specific detail is not captured in the current evidence pack, which records no UK licensing information for the drug. The TxGNN model predicts it may be effective for Obsessive-Compulsive Disorder (OCD), with 30 clinical trials and 16 publications identified in this evidence pack, although most of the trial evidence concerns escitalopram (citalopram’s active enantiomer) rather than citalopram itself.

Quick Overview

Item	Content
Original Indication	Depression (Major Depressive Disorder) — well-established public indication for citalopram; not captured in this evidence pack
Predicted New Indication	Obsessive-Compulsive Disorder (OCD)
TxGNN Prediction Score	99.74%
Evidence Level	L2
UK Market Status	Not marketed (per evidence pack; no MHRA licence records present)
Number of Marketing Authorisations	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in this evidence pack. Based on known pharmacology, citalopram is a selective serotonin reuptake inhibitor (SSRI); its efficacy in depression has long been established, and mechanistically it may be applicable to OCD.

Dysregulation of the serotonergic system is one of the well-established core pathological mechanisms of OCD. Escitalopram, citalopram’s pharmacologically active S-enantiomer, is already approved in several countries for OCD, reflecting a mechanism that is highly transferable between the two molecules. This provides reasonable mechanistic support for the TxGNN prediction, even though direct clinical evidence for citalopram (rather than escitalopram) in OCD remains comparatively limited.

An important caveat flagged directly in the evidence rationale: OCD treatment typically requires SSRI doses higher than the standard antidepressant dose, and citalopram carries a well-documented, dose-dependent risk of QTc prolongation (subject to regulatory dose-ceiling warnings in other jurisdictions). This is a key safety guardrail that must be factored into any repurposing pathway for OCD, where higher-than-standard dosing is often used off-label.

Clinical Trial Evidence

Note: the majority of trials below tested escitalopram, citalopram’s active enantiomer, rather than citalopram itself — relevant supporting evidence for the SSRI class effect, but not direct citalopram data.

Trial Number	Phase	Status	Enrolment	Key Findings
NCT00708240	Phase 4	Unknown (not confirmed completed)	40	Escitalopram efficacy, safety and cognitive/metacognitive changes in adolescents with OCD
NCT02022709	Phase 4	Completed	78	Compared SSRIs, exposure and response prevention (ERP), and combination therapy for OCD; explored predictors of treatment response
NCT00116532	Phase 4	Completed	30	Assessed escitalopram efficacy and optimal dosing for OCD
NCT00115011	Phase 4	Completed	30	Escitalopram for self-injurious skin picking, an OCD-spectrum condition
NCT00680602	Phase 4	Completed	158	Randomised comparison of group CBT versus fluoxetine (an SSRI) for OCD
NCT00723060	Phase 4	Completed	176	Randomised, double-blind comparison of conventional-dose (20 mg) versus high-dose (40 mg) escitalopram in OCD
NCT01936051	N/A	Completed	12	Modelled plasma concentration vs. serotonin transporter occupancy of escitalopram in OCD patients
NCT00708396	Phase 4	Unknown	20	Open-label study of high-dose escitalopram (20–40 mg/day) in patients with comorbid schizophrenia and OCD
NCT00305500	Phase 3	Completed	100	Open-label study of high-dose escitalopram (up to 50 mg/day) for tolerability and efficacy in adult OCD
NCT00074815	Phase 3	Completed	124	Evaluated whether adjunctive CBT improves SRI treatment response in paediatric OCD partial responders

Literature Evidence

PMID	Year	Type	Journal	Key Findings
10572334	1999	Open-label Trial	European Psychiatry	Direct citalopram evidence: citalopram alone vs. citalopram + clomipramine in treatment-resistant OCD (n=16)
10471169	1999	Clinical Report	International Clinical Psychopharmacology	Direct citalopram evidence: reviews citalopram’s use for OCD beyond its depression indication
12839522	2003	Open-label Study	Psychiatry and Clinical Neurosciences	Direct citalopram evidence: 8-week open-label study of citalopram (20–30 mg/day) in children/adolescents with OCD (n=15)
35121274	2022	Network Meta-analysis	Journal of Psychiatric Research	Compared pharmacological and psychological treatments, alone and combined, for paediatric/adolescent OCD
38703743	2024	Review	Comprehensive Psychiatry	Long-term safety and tolerability of off-label high-dose SSRIs in OCD
32982805	2020	Meta-review	Frontiers in Psychiatry	Antidepressant efficacy, tolerability and suicidality in children/adolescents, including OCD
30973183	2019	Neuroimaging Study	Psychiatry and Clinical Neurosciences	1H-MRS brain neurochemistry changes after 12-week escitalopram treatment in unmedicated OCD patients
34313207	2022	Pharmacogenetic Study	CNS Spectrums	BDNF Val66Met polymorphism and response to escitalopram/paroxetine in OCD
12607204	2000	Review	World Journal of Biological Psychiatry	Reviews serotonergic and broader neurobiological mechanisms underlying OCD
22305974	2012	Review	BMJ Clinical Evidence	General clinical evidence review of OCD, including pharmacological treatment

UK Market Information

No marketing authorisation records for citalopram are present in this evidence pack (total_licenses: 0, market status “Not marketed”). Citalopram is, in fact, a long-established generic antidepressant widely available in the UK (BNF section 4.3.3, SSRIs) — but specific MHRA product licence numbers, brand names and SmPC-approved indication text were not returned by the data sources queried for this pack and should be sourced directly from the MHRA Products database before any UK-facing decision is finalised.

Safety Considerations

Known Safety Signal (from evidence rationale): Citalopram carries a well-documented, dose-dependent risk of QTc interval prolongation. This is particularly relevant for a potential OCD indication, since OCD treatment typically requires higher SSRI doses than standard depression dosing, which would amplify cardiac risk.

No further structured safety data (key warnings, contraindications, drug–drug interactions) is available in this evidence pack. Please refer to the SmPC and BNF for full safety information. Report suspected adverse reactions via the Yellow Card Scheme.

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: Direct citalopram evidence in OCD is limited but present (three tier-1 studies, including one RCT-style open-label comparison), and this is substantially reinforced by consistent Phase 3/4 evidence for escitalopram (citalopram’s active enantiomer) across multiple completed trials, supporting a plausible SSRI class effect. However, the evidence pack flags a Blocking data gap (DG001: UK SmPC warnings/contraindications) that currently prevents a full safety assessment, and citalopram itself has no confirmed UK marketing authorisation on record in this pack.

To proceed, the following is needed:

UK/MHRA SmPC safety data (warnings, contraindications) — currently a Blocking data gap (DG001)
Confirmed mechanism-of-action documentation from DrugBank (DG002, High severity)
Verification of citalopram’s actual UK marketing/licensing status (product name, PL number, approved indications)
Additional citalopram-specific (not just escitalopram) trial data in OCD populations, given known enantiomer-specific differences in potency and tolerability
A dose-dependent QTc monitoring plan, given that OCD dosing regimens often exceed standard depression doses

Additional Note: Other Model-Predicted Indications (Not Recommended)

The evidence pack also returned four lower-ranked predictions — paranoid, schizotypal, histrionic and schizoid personality disorder (TxGNN scores ~99.68%, ranks 3666–3669). All are scored Hold with evidence levels L4–L5: little to no clinical trial or literature support exists, and the available literature is either off-topic, comorbidity-context only, or unrelated case reports. These are considered likely artefacts of knowledge-graph clustering among personality-disorder nodes rather than drug-specific signals, and are not recommended for further evaluation at this time.

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.